Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
04:00pm, Wednesday, 10'th Jan 2024
Daix (France), Long Island City (New York, United States), January 10, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on th
The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inventiva. With this milestone payment Inventiva expects t
Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on th
Inventiva reports 2023 Third Quarter Financial Information¹
04:00pm, Tuesday, 21'st Nov 2023
Daix (France), Long Island City (New York, United States), November 21, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on t
Daix (France), Long Island City (New York, United States), November 6, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on th
Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Call Transcript
02:58pm, Friday, 29'th Sep 2023
Inventiva S.A. (NASDAQ:IVA ) Q2 2023 Earnings Analyst Conference Call September 29, 2023 8:00 AM ET Company Participants Frederic Cren - CEO Jean Volatier - CFO Michael Cooreman - Chief Medical Office
Inventiva reports its 2023 first-half financial results and provides a corporate update
04:00pm, Thursday, 28'th Sep 2023
Daix (France), Long Island City (New York, United States), September 28, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on
Inventiva: An Untenable Cash Position Despite Enviable Data
09:01am, Sunday, 16'th Jul 2023
IVA has robust data from a mid-stage NASH trial. They have an ongoing pivotal study running, to topline in H2 2025. They don't have enough cash to complete that trial.
Inventiva S.A. (IVA) 2022 Full Year Results Earnings Call Transcript
01:19pm, Thursday, 30'th Mar 2023
Inventiva S.A. (NASDAQ:IVA ) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financia
Inventiva S.A. (IVA) Q2 2022 Earnings Call Transcript
04:36pm, Thursday, 22'nd Sep 2022
Inventiva S.A. (NASDAQ:IVA ) Q2 2022 Earnings Conference Call September 22, 2022 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Coorema
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
01:35pm, Thursday, 08'th Sep 2022 Zacks Investment Research
Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street an
Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks
11:17am, Thursday, 08'th Sep 2022
Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
Inventiva annonce le screening du premier patient dans l’essai clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de DT2
08:00pm, Thursday, 07'th Jul 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, États-Unis), le 7 juillet 2022 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le dével
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
08:00pm, Thursday, 07'th Jul 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, United States), July 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank
04:45pm, Monday, 04'th Jul 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, United States), July 4, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the de
